SARS-CoV-2 Inhibition by Sulfonated Compounds
1
Institute of Materials, Ecole Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland
2
Institute of Virology and Immunology (IVI), Länggassstrasse 122, 3012 Bern, Switzerland
3
Institute for Infectious Diseases, University of Bern, Hochschulstrasse 6, 3012 Bern, Switzerland
4
Department of Microbiology and Molecular Medicine, University of Geneva, 1211 Geneve, Switzerland
5
Institute of Bioengineering, Ecole Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland
*
Author to whom correspondence should be addressed.
†
These authors contributed equally.
Microorganisms 2020, 8(12), 1894; https://doi.org/10.3390/microorganisms8121894
Received: 30 October 2020
/
Revised: 26 November 2020
/
Accepted: 28 November 2020
/
Published: 30 November 2020
(This article belongs to the Special Issue Recent Advances in Antivirals for Emerging Viruses)
Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) depends on angiotensin converting enzyme 2 (ACE2) for cellular entry, but it might also rely on attachment receptors such as heparan sulfates. Several groups have recently demonstrated an affinity of the SARS-CoV2 spike protein for heparan sulfates and a reduced binding to cells in the presence of heparin or heparinase treatment. Here, we investigated the inhibitory activity of several sulfated and sulfonated molecules, which prevent interaction with heparan sulfates, against vesicular stomatitis virus (VSV)-pseudotyped-SARS-CoV-2 and the authentic SARS-CoV-2. Sulfonated cyclodextrins and nanoparticles that have recently shown broad-spectrum non-toxic virucidal activity against many heparan sulfates binding viruses showed inhibitory activity in the micromolar and nanomolar ranges, respectively. In stark contrast with the mechanisms that these compounds present for these other viruses, the inhibition against SARS-CoV-2 was found to be simply reversible.
View Full-Text
Keywords:
SARS-CoV-2; antiviral; heparan sulfates; attachment inhibitor
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
- Supplementary File 1:
PDF-Document (PDF, 531 KiB)
MDPI and ACS Style
Gasbarri, M.; V’kovski, P.; Torriani, G.; Thiel, V.; Stellacci, F.; Tapparel, C.; Cagno, V. SARS-CoV-2 Inhibition by Sulfonated Compounds. Microorganisms 2020, 8, 1894. https://doi.org/10.3390/microorganisms8121894
AMA Style
Gasbarri M, V’kovski P, Torriani G, Thiel V, Stellacci F, Tapparel C, Cagno V. SARS-CoV-2 Inhibition by Sulfonated Compounds. Microorganisms. 2020; 8(12):1894. https://doi.org/10.3390/microorganisms8121894
Chicago/Turabian StyleGasbarri, Matteo, Philip V’kovski, Giulia Torriani, Volker Thiel, Francesco Stellacci, Caroline Tapparel, and Valeria Cagno. 2020. "SARS-CoV-2 Inhibition by Sulfonated Compounds" Microorganisms 8, no. 12: 1894. https://doi.org/10.3390/microorganisms8121894
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
